GNAS mutations at locus 201 were found in 66% of intraductal papillary mucinous neoplasms. Investigators claim mutations in a gene known as GNAS can help distinguish between nonmalignant pancreatic ...

A research team at Duke Health has identified a set of biomarkers that could help to distinguish whether cysts on the pancreas are likely to develop into cancer or remain benign. The team carried out ...

Asuragen reports data from a study of microRNA biomarkers in pancreatic cyst fluid at the American Pancreatic Association Annual Meeting Austin, Texas - November 3, 2011. Asuragen, Inc. announced ...

Researchers have outlined the comprehensive immune landscape and microbiome of pancreatic cysts as they progress from benign cysts to pancreatic cancer. The findings could reveal the mechanism of ...

Developing cell-free DNA (cfDNA) epigenetic signature (ep-Sig) for early detection of malignant transformation of intraductal papillary mucinous neoplasms (IPMN). Pancreatic biopsy evaluation with ...

The study also included measurement of four protein markers present in the cyst fluid. All four proteins were overexpressed in the high-risk versus the low-risk group (P < .001). Adding the findings ...

The ever-increasing use of radiographic imaging of the abdomen, in particular by CT and MRI, has led to a significant rise in the discovery of patients with pancreatic cysts. Often these are ...

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a leader in exosome enrichment technology for early disease detection, will present a “lightning talk” as part of the “Understanding Pre-cancers ...

Please provide your email address to receive an email when new articles are posted on . Pancreatic cystic lesions are being diagnosed with increasing frequency in asymptomatic patients or incidentally ...

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today proudly announces that the ...